PROBES FOR METABOLIC MARKERS OF ANTIBIOTIC RESISTANCE

Information

  • Research Project
  • 3489731
  • ApplicationId
    3489731
  • Core Project Number
    R43AI034190
  • Full Project Number
    1R43AI034190-01
  • Serial Number
    34190
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1993 - 31 years ago
  • Project End Date
    10/31/1993 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1993 - 31 years ago
  • Budget End Date
    10/31/1993 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/31/1993 - 31 years ago
Organizations

PROBES FOR METABOLIC MARKERS OF ANTIBIOTIC RESISTANCE

The aim is to evaluate a novel technology for testing the susceptibility of prokaryotes to certain antibiotics, with the goal of developing rapid antibiotic susceptibility tests for Mycobacterium tuberculosis and other pathogens. The technology will rapidly detect growth of resistant bacteria challenged with antibiotics in pure of mixed cultures, using oligonucleotide probes for two RNA targets: ribosomal RNA precursors (pre-rRNA), and mature ribosomal RNA (rRNA). Cellular copy number of pre-rRNA sequences are very sensitive to rifampicin, declining rapidly upon exposure from high to undetectable levels. By probing for these sequences in cells challenged briefly with rifampicin, it will be possible to detect growing (resistant) cells in a single measurement. Mature rRNA has species-specific sequences useful for detection of bacteria in mixed cultures containing other species. Probes for mature rRNA will be combined with probes for pre-rRNA in a rapid, sensitive, easy-to-use assay that simultaneously identifies bacterial species in primary enrichment cultures, and determines their susceptibility to rifampicin and other antibiotics. Such a test would predict the outcome of antibiotic treatment much more rapidly and accurately than conventional tests. In Phase I of the project, we will test the feasibility of the concept using a fast-growing, well characterized bacterium, Escherichia coli. Experiments will focus initially on resistance to rifampicin, one of the "first-line" antibiotics for treatment of tuberculosis, and then on other antibiotics. In Phase II, we will transfer the technology to the more challenging Mycobacterium tuberculosis system. Ultimately, we will apply the technology to other clinically important microorganisms as well.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    EPOCH BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    980213906
  • Organization District
    UNITED STATES